Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned an average rating of “Reduce” from the ten analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a hold recommendation on the company.

Separately, The Goldman Sachs Group began coverage on Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They set a “neutral” rating for the company.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY opened at $7.43 on Tuesday. Bayer Aktiengesellschaft has a 1-year low of $6.82 and a 1-year high of $14.70. The company has a quick ratio of 0.87, a current ratio of 1.31 and a debt-to-equity ratio of 1.06. The business’s fifty day moving average price is $7.30 and its two-hundred day moving average price is $7.56.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, May 14th. The company reported $0.77 earnings per share for the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. The business had revenue of $14.95 billion for the quarter. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.35 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.